Tectonic Therapeutic, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TECTONIC THERAPEUTIC, INC. | ||
| Date: February 26, 2026 | By: | /s/ Alise Reicin, M.D. |
|---|---|---|
| Alise Reicin, M.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: February 26, 2026 | By: | /s/ Daniel Lochner |
| Daniel Lochner | ||
| Chief Financial Officer | ||
| (Principal Financial Officer and PrincipalAccounting Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alise Reicin and Daniel Lochner, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable Tectonic Therapeutic, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
| Signature | Title | Date |
|---|---|---|
| /s/ Alise Reicin | President, Chief Executive Officer and Director | February 26, 2026 |
| Alise Reicin | (Principal Executive Officer) | |
| /s/ Daniel Lochner | Chief Financial Officer | February 26, 2026 |
| Daniel Lochner | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Terrance McGuire | Director | February 26, 2026 |
| Terrance McGuire | ||
| /s/ Stefan Vitorovic | Director | February 26, 2026 |
| Stefan Vitorovic | ||
| /s/ Timothy A. Springer | Director | February 26, 2026 |
| Timothy A. Springer | ||
| /s/ Praveen Tipirneni | Director | February 26, 2026 |
| Praveen Tipirneni | ||
| s/ Phillip B. Donenberg | Director | February 26, 2026 |
| Phillip B. Donenberg | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.